Advertisement

Helicobacter pylori Eradication Therapy

  • Jia-Qing Huang
  • Richard H. Hunt
Part of the Infectious Agents and Pathogenesis book series (IAPA)

Abstract

Helicobacter pylori (H. pylori)infection is a well recognized upper gastrointestinal pathogen. Eradication of the infection heals type B chronic active gastritis, peptic ulcer disease and virtually abolishes ulcer recurrence.1–5Cure of the infection also results in a complete histological regression of gastric MALT lymphoma in 80% of the patients and prevents recurrence in almost all cases6–8and may prevent metachronous occurrence of gastric adenocarcinoma following endoscopic resection of early gastric cancer.9

Keywords

Pylorus Infection Triple Therapy Pylorus Eradication Eradication Rate Gastric Malt Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hunt R. H., and Lam S. K., 1998,Helicobacter pylori:from art to a science.J. Gastroenterol. Hepatol.13(l):21–28.PubMedCrossRefGoogle Scholar
  2. 2.
    Genta R. M., Lew G. M., and Graham D. Y., 1993, Changes in the gastric mucosa following eradication ofHelicobacter pylori. Modern Pathol.6(3):281–289.Google Scholar
  3. 3.
    Labenz J., and Borsch G., 1994, Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure ofHelicobacter pyloriinfection.Am. J. Gastroenterol.89(10):1785–1788.PubMedGoogle Scholar
  4. 4.
    Huang J. Q., Sridhar S., Wilkinson J., Chen Y., and Hunt R. H., 1996, Antibiotics accelerate healing of duodenal ulcer (DU) when combined with proton pump inhibitors (PPI) or H2-receptor antagonists (H2RAs).Gastroenterol.110(4):A137.Google Scholar
  5. 5.
    Huang J. Q., and Hunt R. H., 1996, Does initial choice ofHelicobacter pyloritreatment regimen influence the recurrence rate of duodenal ulcer? A meta-analysis.Gut.39(suppl 3):A142(808).Google Scholar
  6. 6.
    Huang J. Q., Sheldon A., and Hunt R. H., 1997, Is there a causal relationship between H. pyloriinfection and gastric maltoma? A meta-analysis of the evidence from epidemiological studies and clinical trials.Gut.41(suppl 1):A49(04/179).Google Scholar
  7. 7.
    Stolte M., Morgner A., Meining A., Thiede C. H., Wündisch T. H., BayerdörfFer E., and Neubauer A., 1998, Early and long-term results of Helicobacter pylori cure of MALT lymphoma What are the pitfalls. In: Hunt R. H., Tytgat G. N.J. eds.Helicobacter pylori: Basic Mechanisms to Clinical Cure. Kluwer Academic Publishers, London, pp 373–382.CrossRefGoogle Scholar
  8. 8.
    Neubauer A., Thiede C., Morgner A., Alpen B., Ritter M., Neubauer B., Wundisch T., Ehninger G., Stolte M., and BayerdörfFer E., 1997, Cure ofHelicobacter pyloriinfection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma.J. Natl. Cancer Inst.Sep 17;89(18):1350–1355.PubMedCrossRefGoogle Scholar
  9. 9.
    Uemura N., Mukai T., Okamoto S., Yamaguchi S., Mashiba H., Taniyama K., Sasaki N., Haruma K., Sumii K., and Kajiyama G., 1997, Effect ofHelicobacter pylorieradication on subsequent development of cancer after endoscopic resection of early gastric cancer.Cancer Epidemiol. Biomarkers Prev.6(8):639–642.PubMedGoogle Scholar
  10. 10.
    McNulty C. A. M., Gearty J. C., Crump B., Davis M., Donovan I. A., Melikian V., Lister D. M., and Wise R., 1986,Campylobacterpyloridisand associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.BMJ 293(6548):645–649.PubMedCrossRefGoogle Scholar
  11. 11.
    Huang J. Q., and Hunt R. H., 1997, Review: eradication of Helicobacter pylori: problems and recommendations.J. Gastroenterol. Hepatol.12:590–598.PubMedCrossRefGoogle Scholar
  12. 12.
    Hunt R. H., 1996, Eradication ofHelicobacter pyloriinfection.Am. J. Med.100(suppl 5A):42–51.Google Scholar
  13. 13.
    Peura D. A., and the American Digestive Health Foundation, 1997, The report of the Digestive Health InitiativeSMinternational update conference onHelicobacter pylori. Gastroenterol.113:S4–S8.CrossRefGoogle Scholar
  14. 14.
    Hunt R. H., and Thomson A. B. R., 1998, CanadianHelicobacter pyloriconsensus conference.Can. J. Gastroenterol.12(1):31–41.PubMedGoogle Scholar
  15. 15. Current European concepts in the management ofHelicobacter pyloriinfection. The Maastricht Consensus Report. EuropeanHelicobacter PyloriStudy Group.Gut. Jul.41(1):8–13.Google Scholar
  16. 16.
    Lam S. K., and Talley N. J., 1998,Helicobacter pyloriconsensus: Report of the 1997 Asia Pacific consensus conference on the management ofHelicobacter pyloriinfection.J. Gastroenterol. Hepatol.13:1–12.PubMedCrossRefGoogle Scholar
  17. 17.
    Huangand J. Q, and Hunt R. H., 1999, Treatment after failure: the problem of “non-responders”.Gut.45(suppl l):40–44.CrossRefGoogle Scholar
  18. 18.
    Huang J. Q., and Hunt R. H., 1998, Are one week anti-H. pyloritreatments more effective in patients with peptic ulcer disease (PUD) than in those with non-ulcer dyspepsia (NUD)? A meta-analysis.Am. J. Gastroenterol.93(9):1639(abstract 119).Google Scholar
  19. 19.
    Chiba N., Rao B. V., Rademaker J. W., and Hunt R. H., 1992, Meta-analysis of the efficacy of antibiotic therapy in eradicatingHelicobacter pylori. Am. J. Gastroenterol.87(12):1716–1727.PubMedGoogle Scholar
  20. 20.
    Chiba N., and Hunt R. H., 1999, Drug therapy ofHelicobacter pyloriinfection: A meta-analysis. In: Scarpignato C, Bianchi Porro G. (eds), Clinical Pharmacology and Therapy ofHelicobacter pyloriInfection.Prog. Basic Clin. Pharmacol. Basel, Karger, vol 11, pp 227–268.Google Scholar
  21. 21.
    Lind T., Megraud F., Unge P., Bayerdorffer E., O’morain C., Spiller R., Veldhuyzen Van Zanten S., Bardhan K. D., Hellblom M., Wrangstadh M., Zeijlon L., and Cederberg C., 1999, The MACH2 study: role of omeprazole in eradication ofHelicobacter pyloriwith 1-week triple therapies.Gastroenterol.116(2):248–253.CrossRefGoogle Scholar
  22. 22.
    Schmid C. H., Whiting G., Cory D., Ross S. D., and Chalmers T. C., 1999, Omeprazole plus antibiotics in the eradication of Helicobacter pylori infection: a meta-regression analysis of randomized, controlled trials.Am. J. Ther.6(l):25–36.PubMedCrossRefGoogle Scholar
  23. 23.
    Lamouliatte H., Cayla R., Zerbib F., Forestier S., de Mascarel A., Joubert-Collin M., and Megraud F., 1998, Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicateHelicobacter pyloriinfection: results of a prospective randomized open study.Am. J. Gastroenterol.93(9):1531–1534.PubMedCrossRefGoogle Scholar
  24. 24.
    Schwartz H., Krause R., Sahba B., Haber M., Weissfeld A., Rose P., Siepman N., and Freston J., 1998, Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.Am. J. Gastroenterol.93(4):584–590.PubMedCrossRefGoogle Scholar
  25. 25.
    Wong B. C., Xiao S. D., Hu F. L., Qian S. C., Huang N. X., Li Y. Y., Hu P. J., Manan C., Lesmana, Carpio R. E., Perez J. Y., Fock K. M., Kachintorn U. K., Phornphutkul M., Kullavanijaya, Ho J., and Lam S. K., 2000, Comparison of lansoprazole-based triple and dual therapy for treatment ofHelicobacter pylori-relatedduodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study.Aliment. Pharmacol. Ther.14(2):217–224.PubMedCrossRefGoogle Scholar
  26. 26.
    Calvet X., Lopez-Lorente M., Cubells M., Bare M., Galvez E., and Molina E., 1999, Two-week individual vs. one-week triple therapy for cure ofHelicobacter pyloriinfection in primary care: a multicentre, randomized trial.Aliment. Pharmacol. Ther.13(6):781–786.PubMedCrossRefGoogle Scholar
  27. 27.
    Hunt R. H., 1993, pH and Hp—gastric acid secretion andHelicobacter pylori: implications for ulcer healing and eradication of the organism.Am. J. Gastroenterol.88(4):481–483.PubMedGoogle Scholar
  28. 28.
    Hunt R. H., 1993, Hp and pH: implications for the eradication ofHelicobacter pylori. Scand. J. Gastroenterol. Suppl.196:12–16.CrossRefGoogle Scholar
  29. 29.
    Nagata K., Takagi E., Tsuda M., Nakazawa T., Satoh H., Nakao M., Okamura H., Tamura T, 1995, Inhibitory action of lansoprazole and its analogs againstHelicobacter pylori: inhibition of growth is not related to inhibition of urease.Antimicrob. Agents Chemother.39(2):567–570.PubMedCrossRefGoogle Scholar
  30. 30.
    Houben M. H., Van Der Beek D., Hensen E. F., Craen A. J., Rauws E. A., and Tytgat G. N., 1999, A systematic review of Helicobacter pylori eradication therapy—the impact of antimicrobial resistance on eradication rates.Aliment. Pharmacol. Ther.13(8):1047–1055.PubMedCrossRefGoogle Scholar
  31. 31.
    Huang J., and Hunt R. H., 1999, The importance of clarithromycin dose in the management ofHelicobacter pyloriinfection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.Aliment. Pharmacol. Ther.13(6):719–729.PubMedCrossRefGoogle Scholar
  32. 32. Huang J. Q., Chiba N., Wilkinson J. M., and Hunt R. H., 1997, Which combination therapy can eradicate 90%Helicobacter pyloriinfection? A meta-analysis of amoxicillin, metronidazole, tetracycline and clarithromycin containing regimens.Gastroenterol.112(4):A19.Google Scholar
  33. 33.
    de Boer W. A., 1999, Quadruple therapy: second- or first-line eradication regimen? In: Scarpignato C., and Bianchi Porro G. (eds), Clinical Pharmacology and Therapy ofHelicobacter pyloriInfection.Prog. Basic Clin. Pharmacol. Basel, Karger, vol 11, pp 212–226.Google Scholar
  34. 34.
    Fennerty M. B., Kovacs T. O., Krause R., Haber M., Weissfeld A., Siepman N., Rose P., 1998, A comparison of 10 and 14 days of lansoprazole triple therapy for eradication ofHelicobacter pylori. Arch. Intern. Med. 10–24;158(15):1651–1656.PubMedCrossRefGoogle Scholar
  35. 35.
    Laine L., Estrada R., Trujillo M., Fukanaga K., and Neil G., 1996, Randomized comparison of differing periods of twice-a-day triple therapy for the eradication ofHelicobacter pylori. Aliment. Pharmacol. Ther.10(6):1029–1033.PubMedCrossRefGoogle Scholar
  36. 36.
    Graham D., Lew G. M., Malaty H. M. ,et al.,1992, Factors influencing the eradication ofHelicobacter pyloriwith triple therapy.Gastroenterol.102:493–496.Google Scholar
  37. 37.
    Buring S. M., Winner L. H., Hatton R. C., and Doering P. L., 1999, Discontinuation rates ofHelicobacter pyloritreatment regimens: A meta-analysis.Pharmacotherapy 19(3):324–332.PubMedCrossRefGoogle Scholar
  38. 38.
    Houben M. H. M. G., van de Beek D., Hensen E. F., de Craen A. J. M., Rauws E. A. J., and Tytgat G. N.J., 1999, A systematic review ofHelicobacter pylorieradication therapy—the impact of antimicrobial resistance on eradication rates.Aliment. Pharmacol. Ther.13:1047–1055.PubMedCrossRefGoogle Scholar
  39. 39.
    Huang J. Q., and Hunt R. H., 1999, Impact of metronidazole-resistant (M-R)H. pyloristrains on proton pump inhibitor (PPI)-based triple therapies: A meta-analysis.Am. J. Gastroenterol.94(9):2752 (abstract 702).Google Scholar
  40. 40.
    Huang J. Q., and Hunt R. H., 1999, Predicting treatment failure with PPI-based triple therapies in metronidazole-resistantH. pyloriinfections: A model based on trial meta-analysis data.Am. J. Gastroenterol.94(9):2753 (abstract 703).Google Scholar
  41. 41.
    Marais A., Monteiro L., Lamouliatte H., Samoyeau R., and Méraud F., 1998, Cag negative status ofHelicobacter pyloriis a risk factor for failure of PPI-based triple therapies in non-ulcer dyspepsia.Gastroenterol.114(4):A214.Google Scholar
  42. 42.
    van Doom L.-J., Schneeberger P. M., Nouhan N., Plaisier A. P., Quint W. G. V., deBoer W. A., 2000, Importance ofHelicobacter pylori cagAandvacAstatus for the efficacy of antibiotic treatment.Gut.46:321–326.CrossRefGoogle Scholar
  43. 43.
    Go M. F., and Graham D. Y., 1996, Presence of the cagA gene in the majority ofHelicobaterpyloristrains is independent of whether the individual has duodenal ulcer or asymptomatic gastritis.Helicobacter 1(2):107–111.PubMedCrossRefGoogle Scholar
  44. 44.
    Yoshimura H. H., Evans D. G., and Graham D. Y., 1993, DNA-DNA hybridization demonstrates apparent genetic differences betweenHelicobacter pylorifrom patients with duodenal ulcer and asymptomatic gastritis.Dig. Dis. Sci.38:1128–1131.PubMedCrossRefGoogle Scholar
  45. 45.
    Williamson R., and Pipkin G. A., 1998, Does bismuth prevent antimicrobial resistance ofHelicobacter pylori? In: Hunt R. H., Tytgat G N. J. eds.Helicobacter pylori: Basic Mechanisms to Clinical Cure. Kluwer Academic Publishers, London, pp 416–425.CrossRefGoogle Scholar
  46. 46.
    Chiba N., and Hunt R. H., 1999, Ulcer disease andHelicobacter pyloriinfection: etiology and treatment. In: McDonald J. W. D., Burroughs A., and Feagan B. (eds), Evidence Based Gastroenterology and Hepatology. Chapter 2, 66–90.B.M.J. Books.Google Scholar
  47. 47.
    Pare P., Farley A., Romaozinho J. M., Bardhan K. D., French P. C., Roberts P. M., 1999, Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication ofHelicobacter pylori. Aliment. Pharmacol. Ther.13(8):1071–1078.PubMedCrossRefGoogle Scholar
  48. 48.
    Schwartz H. I., Perschy T. B., McSorley D. J., and Sorrells S. C., 1999, Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication ofHelicobacter pylori. Helicobacter 4(2):121–127.PubMedCrossRefGoogle Scholar
  49. 49.
    Pipkin G. A., Williamson R., and Wood J. R., 1998, Review article: one-week clarithromycin triple therapy regimens for eradication ofHelicobacter pylori. Aliment. Pharmacol. Ther.12(9):823–837.PubMedCrossRefGoogle Scholar
  50. 50.
    Huang J. Q., and Hunt R. H., 1999, Letter: Clarithromycin-based triple therapies.Aliment. Pharmacol. Ther.13(3):437–438.PubMedCrossRefGoogle Scholar
  51. 51.
    Huang J. Q., and Hunt R. H., 1999, Letter: Clarithromycin-based triple therapies.Aliment. Pharmacol. Ther.13(3):437–438.PubMedCrossRefGoogle Scholar
  52. 52.
    Sung J. J., Chan F. K., Wu J. C., Leung W. K., Suen R., Ling T. K., Lee Y. T., Cheng A. F., and Chung S. C., 1999, One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment ofHelicobacter pyloriinfection: the RBC-MACH study.Aliment. Pharmacol. Ther.13(8):1079–1084.PubMedCrossRefGoogle Scholar
  53. 53.
    Kung N. N., Sung J. J., Yuen N. W., Li T. H., Ng P. W., Lai W. M., Lui Y. H., Lam K. N., Choi H., and Leung E. M., 1999, One-week ranitidine bismuth citrate vs. colloidal bismuth subcitrate-based anti-Helicobactertriple therapy: a prospective randomized controlled trial.Am. J. Gastroenterol.94(3):721–724.PubMedCrossRefGoogle Scholar
  54. 54.
    Lopez-Brea M., Domingo D., Sanchez I., Prieto N., and Alarcon T., 1998, Study of the combination of ranitidine bismuth citrate and metronidazole against metronidazole-resistantHelicobacter pyloriclinical isolates. J.Antimicrob. Chemother.42(3):309–314.PubMedCrossRefGoogle Scholar
  55. 55.
    Megraud F., 1999, Resistance ofHelicobacter pylorito antibiotics: the main limitation of current-proton-pump inhibitor triple therapy.Eur. J. Gastroenterol. Hepatol.11Suppl 2:S35–S37; discussion S43–S45.CrossRefGoogle Scholar
  56. 56.
    Liu W. Z., Xiao S. D., Shi Y., Wu S. M., Zhang D. Z., Xu W. W., and Tytgat G. N., 1999, Furazolidone-containing short-term triple therapies are effective in the treatment ofHelicobacter pyloriinfection.Aliment. Pharmacol. Ther.13(3):317–322.PubMedCrossRefGoogle Scholar
  57. 57.
    Xiao S. D., Liu W. Z., Hu P. J., Xia D. H., and Tytgat G. N., 1999, High cure rate ofHelicobacter pyloriinfection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week.Aliment. Pharmacol. Ther. Mar.13(3):311–315.PubMedCrossRefGoogle Scholar
  58. 58.
    Dani R., Queiroz D. M., Dias M. G., Franco J. M., Magalhaes L. C., Mendes G. S., Moreira L. S., De Castro L. P., Toppa N. H., Rocha G. A., Cabrai M. M., and Salles P. G., 1999, Omeprazole, clarithromycin and furazolidone for the eradication ofHelicobacter pyloriin patients with duodenal ulcer.Aliment. Pharmacol. Ther. Dec.13(12):1647–1652.PubMedCrossRefGoogle Scholar
  59. 59.
    Perri F., Festa V., Andriulli A., 1998, Treatment of antibiotic-resistantHelicobacter pylori. M Engl. J. Med. Jul.2;339(1):53.CrossRefGoogle Scholar
  60. 60.
    Graham D. Y., Osato M. S., Hoffman J., Opekun A. R., Anderson S., and El-Zimaity H. M., 2000, Furazolidone combination therapies forHelicobacter pyloriinfection in the United States.Aliment Pharmacol. Ther. Feb;14(2):211–215.PubMedCrossRefGoogle Scholar
  61. 61.
    De Boer W. A., van Etten R. J. X. M., Schneeberger P. M., and Tytgat G. N. J., 2000, A single drug forHelicobacter pyloriinfection: first results with a new bismuth triple monocapsule.Am. J. Gastroenterol.95(3):641–645PubMedCrossRefGoogle Scholar
  62. 62.
    Laine L., RifT D., Stanton D., Lamet M., Farley A., Korcek W., Schuman R., Piotrowski J., Dallaire C., Fallone C., Archambault A., Cockeram C., Fay D., Olsheski W., Barkun A., Bradette M., Gaddam S., Lahaie R., Ponich T., van Zanten S., Pulverman S., Chiba N., Thomson A., Bianchi T., Graham D., Murali N., Bernstein C., Zidel B., McHattie J., Provenza M., Rapier R., Taub W, Taunk J., Watier A., Hunt R.et al., 2000, Bismuth based single capsule triple therapy in North America: interim results of a North American study of OBMT vs OAC.Helicobacter pylori: Basic mechanisms to clinical cure 2000, Bermuda, March 26–29.Google Scholar
  63. 63.
    Chan F. K., Sung J. J., Suen R., Wu J. C., Ling T. K., and Chung S. C., 2000, Salvage therapies after failure ofHelicobacter pylorieradication with ranitidine bismuth citrate-based therapies.Aliment. Pharmacol. Ther.Jan.14(l):91–95.PubMedCrossRefGoogle Scholar
  64. 64.
    Miyaji H., Azuma T., Ito S., Suto H., Ito Y., Yamazaki Y., Sato F., Hirai M., Kuriyama M., Kato T., and Kohli Y., 1997, Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan.Aliment. Pharmacol. Ther. Dec.11(6):1131–1136.PubMedCrossRefGoogle Scholar
  65. 65.
    Moshkowitz M., Konikoff F. M., Peled Y., Brill S., Hallak A., Tiomny E., Santo M., Bujanover Y., and Gilat T., 1996, One week triple therapy with omeprazole, clarithromycin and tinidazole forHelicobacter pylori: differing efficacy in previously treated and untreated patients.Aliment. Pharmacol. Ther. Dec.10(6):1015–1019.PubMedCrossRefGoogle Scholar
  66. 66.
    de Boer W. A., and Tytgat G. N. J., Treatment ofHelicobacter pyloriinfection.B.M.J.320:31–34.Google Scholar
  67. 67.
    From Huang J., and Hunt R. H., 1999, The importance of clarithromycin dose in the management ofHelicobacter pyloriinfection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.Aliment. Pharmacol Ther. Jun.13(6):719–729.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Jia-Qing Huang
    • 1
  • Richard H. Hunt
    • 1
  1. 1.Division of Gastroenterology, Department of MedicineMcMaster University Medical CenterHamiltonCanada

Personalised recommendations